LLY

1,008.91

-3.56%↓

JNJ

245.26

-2.05%↓

ABBV

233.8

+0.06%↑

NVS

162.28

-2.9%↓

MRK

119.83

-2.59%↓

LLY

1,008.91

-3.56%↓

JNJ

245.26

-2.05%↓

ABBV

233.8

+0.06%↑

NVS

162.28

-2.9%↓

MRK

119.83

-2.59%↓

LLY

1,008.91

-3.56%↓

JNJ

245.26

-2.05%↓

ABBV

233.8

+0.06%↑

NVS

162.28

-2.9%↓

MRK

119.83

-2.59%↓

LLY

1,008.91

-3.56%↓

JNJ

245.26

-2.05%↓

ABBV

233.8

+0.06%↑

NVS

162.28

-2.9%↓

MRK

119.83

-2.59%↓

LLY

1,008.91

-3.56%↓

JNJ

245.26

-2.05%↓

ABBV

233.8

+0.06%↑

NVS

162.28

-2.9%↓

MRK

119.83

-2.59%↓

Kodu・Aktsiate loetelu・Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc

Suletud

SektorTervishoid

41.56 -3.24

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

42.29

Max

43.84

Põhinäitajad
By Trading Economics
Sissetulek	-6.2M -91M
Kasumimarginaal	-867.293
Töötajad	316
EBITDA	4M -90M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+32.67% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	5. märts 2026

Turustatistika
By TradingEconomics
Turukapital	71M 3.3B
Eelmine avamishind	44.8
Eelmine sulgemishind	41.56

Uudiste sentiment

By Acuity

50%

155 / 352 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

34.81 / 38.24 Toetus ja vastupanu

Xenon Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

2. märts 2026, 23:41 UTC

Market Talk

Uudisväärsed sündmused

Nikkei May Decline on Concerns About Energy Prices -- Market Talk

2. märts 2026, 23:37 UTC

Market Talk

Uudisväärsed sündmused

Gold Edges Higher Amid Middle East Conflict -- Market Talk

2. märts 2026, 23:26 UTC

Uudisväärsed sündmused

How the Iran Conflict Could Pressure Consumer Staples Companies -- Barrons.com

2. märts 2026, 22:41 UTC

Market Talk

Australian Reits Wait on Recovery in Trading Multiples -- Market Talk

2. märts 2026, 22:32 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

2. märts 2026, 22:32 UTC

Market Talk

RBA Cautious About Potential for Energy Supply Shocks -- Market Talk

2. märts 2026, 22:21 UTC

Market Talk

Port of Tauranga's Upgraded Profit View Still Looks Conservative -- Market Talk

2. märts 2026, 22:11 UTC

Market Talk

Global Equities Roundup: Market Talk

2. märts 2026, 22:11 UTC

Market Talk

Don't Lose Sight of Bigger Picture With Summerset -- Market Talk

2. märts 2026, 22:10 UTC

Omandamised, ülevõtmised, äriostud

IAC Is Near Deal to Sell Care.com to Private-Equity Firm -- WSJ

2. märts 2026, 22:06 UTC

Market Talk

Channel Infrastructure's Dividend Positively Surprises -- Market Talk

2. märts 2026, 22:00 UTC

Market Talk

Tulu

Global Forex and Fixed Income Roundup: Market Talk

2. märts 2026, 22:00 UTC

Market Talk

Tulu

Fashion Retailer Hallenstein Glasson Still a Smart Buy -- Market Talk

2. märts 2026, 21:50 UTC

Market Talk

Uudisväärsed sündmused

Energy & Utilities Roundup: Market Talk

2. märts 2026, 21:50 UTC

Market Talk

Uudisväärsed sündmused

Basic Materials Roundup: Market Talk

2. märts 2026, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

2. märts 2026, 21:35 UTC

Omandamised, ülevõtmised, äriostud

AT&T Expects Net Debt-To-Adjusted Ebitda Ratio Will Rise to About 3.2x Following Deal With EchoStar and Decline to About 3x by End of 2026

2. märts 2026, 21:34 UTC

Omandamised, ülevõtmised, äriostud

AT&T Remains on Track to Achieve Its 2026 and Multi-Yr Fincl Guidance

2. märts 2026, 21:30 UTC

Omandamised, ülevõtmised, äriostud

Update: AES to Be Taken Private in $33 Billion Deal. Why It's the S&P 500's Worst Stock Today. -- Barrons.com

2. märts 2026, 21:17 UTC

Uudisväärsed sündmused

Bank, Brokerage Stocks Recover Lost Ground After Last Week's Selloff -- Despite Iran Conflict -- Barrons.com

2. märts 2026, 20:44 UTC

Tulu

Berkshire Stock Falls 5% as Earnings, Abel Letter Fail to Excite Investors -- Barrons.com

2. märts 2026, 20:43 UTC

Market Talk

Uudisväärsed sündmused

Treasury Yields Fall, Dollar Strengthens After Attack on Iran -- Market Talk

2. märts 2026, 20:28 UTC

Tulu

Strategy Stock Rises. The World's Largest Bitcoin Holder Doubles Down on Its Crypto Bet. -- Barrons.com

2. märts 2026, 20:25 UTC

Market Talk

Uudisväärsed sündmused

U.S. Natural Gas Futures Post Moderate Gains -- Market Talk

2. märts 2026, 20:24 UTC

Tulu

Berkshire Stock Falls 5% as Earnings, Abel Letter Fail to Excite Investors -- Barrons.com

2. märts 2026, 20:14 UTC

Omandamised, ülevõtmised, äriostud

Update: AES to Be Taken Private in $33 Billion Deal. Why It's the S&P 500's Worst Stock Today. -- Barrons.com

2. märts 2026, 20:12 UTC

Uudisväärsed sündmused

Palantir Rises on Mideast Conflict. Why It's Moving Like a Defense Stock. -- Barrons.com

2. märts 2026, 20:08 UTC

Market Talk

Uudisväärsed sündmused

Global Forex and Fixed Income Roundup: Market Talk

2. märts 2026, 20:08 UTC

Market Talk

Uudisväärsed sündmused

Higher Oil Prices Could Boost Capex in Canada Energy Patch -- Market Talk

2. märts 2026, 20:05 UTC

Market Talk

Uudisväärsed sündmused

Oil Rises On U.S.-Middle East Conflict, But Settles Off Highs -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Xenon Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

32.67% tõus

12 kuu keskmine prognoos

Keskmine 56.45 USD 32.67%

Kõrge 66 USD

Madal 44 USD

Põhineb 14 Wall Streeti analüütiku instrumendi Xenon Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

14 ratings

Osta

Hoia

Müü

Põhineb 14 analüütiku instrumendi Xenon Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

34.81 / 38.24Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

155 / 352 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.